Showing 3981-3990 of 9116 results for "".
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal
- JAK Inhibition, Durable Repigmentation Strategies Among Vitiligo Advanceshttps://practicaldermatology.com/news/jak-inhibition-durable-repigmentation-strategies-among-vitiligo-advances/2484093/Vitiligo has entered a new era of treatment innovation, according to Seemal Desai, MD, FAAD, who presented “Vitiligo Spotlight: A Closer Look at JAK Inhibitors” at the 2025 Fall Clinical Dermatology Conference. Dr. Desai characterized the current moment as a “Renaissance period” in vitilig
- Long-Term Baricitinib Data Reinforce Potential in Adolescents With AAhttps://practicaldermatology.com/news/long-term-baricitinib-data-reinforce-potential-in-adolescents-with-aa/2484088/More than half of adolescents treated for alopecia areata (AA) with baricitinib 4mg achieved successful scalp hair response by Week 52, with a response rate reaching 71% among those with baseline Severity of Alopecia Tool (SALT) score of 50-94, according to new data presented at the 2025 Fall Cli
- Arcutis Presents New ZORYVE Data in AD at Fall Clinical 2025https://practicaldermatology.com/news/arcutis-presents-new-zoryve-data-in-ad-at-fall-clinical-2025/2484062/Updates and new data sets from the INTEGUMENT trial program, including new quality-of-life and efficacy data for ZORYVE® (roflumilast) cream in pediatric and adult patients with atopic dermatitis (AD), were featured at the 2025 Fall Clinical Dermatology Conference
- Hydrocolloid Dressings After Mohs Surgery Yield No Aesthetic Advantage: Studyhttps://practicaldermatology.com/news/hydrocolloid-dressings-after-mohs-surgery-yield-no-aesthetic-advantage-study/2484049/Hydrocolloid dressings (HCDs) and daily petroleum ointment following excisional dermatologic surgery did not perform differently in terms of scar appearance or surgical complications, according to a new trial. The randomized,
- Dr. Woolery-Lloyd Appointed Program Development Advisor for Skin of Color Updatehttps://practicaldermatology.com/news/dr-woolery-lloyd-appointed-program-development-advisor-for-skin-of-color-update/2484015/Heather Woolery-Lloyd, MD, FAAD, has been appointed program development advisor for Skin of Color Update, the nation’s largest medical education event focused on dermatologic care for patients with skin of color. Dr. Woolery-Lloyd serves as director of the Skin of Color Division at the Uni
- Analysis: Long-Term Ixekizumab Not Linked to Higher Cancer Risk in PsO, PsAhttps://practicaldermatology.com/news/analysis-long-term-ixekizumab-not-linked-to-higher-cancer-risk-in-pso-psa/2483983/A recent pooled analysis of 25 randomized clinical trials (RCTs) found no increased risk of malignant neoplasms with long-term ixekizumab (IXE) therapy in patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
- Study: Epidermal Mitochondrial Loss Linked to Skin Aging and Fat Gainhttps://practicaldermatology.com/news/study-epidermal-mitochondrial-loss-linked-to-skin-aging-and-fat-gain/2483941/A new study published in the Journal of Investigative Dermatology suggests mitochondrial decline in epidermal keratinocytes plays a central role in skin aging and may also contribute to age-related obesity.